CN Patent

CN113620972A — 瑞卢戈利新晶型及其制备方法

Assigned to Yangzhou Aoruite Pharmaceutical Co ltd · Expires 2021-11-09 · 5y expired

What this patent protects

本发明涉及瑞卢戈利新晶型及制备方法。具体地，本发明提供了瑞卢戈利(式I化合物)的三种新晶型APTI‑I、APTI‑II、APTI‑III及其制备方法。本发明的晶型APTI‑II、APTI‑III除杂效果好。三种晶型均易于制备、操作简便，均适用于工业化大生产。

USPTO Abstract

本发明涉及瑞卢戈利新晶型及制备方法。具体地，本发明提供了瑞卢戈利(式I化合物)的三种新晶型APTI‑I、APTI‑II、APTI‑III及其制备方法。本发明的晶型APTI‑II、APTI‑III除杂效果好。三种晶型均易于制备、操作简便，均适用于工业化大生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN113620972A
Jurisdiction
CN
Classification
—
Expires
2021-11-09
Drug substance claim
No
Drug product claim
No
Assignee
Yangzhou Aoruite Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.